Australia's Clarity Pharmaceuticals rises on cancer product progress

Clarity Pharmaceuticals

05/06/2025 03:59

** Shares of Clarity Pharmaceuticals CU6.AX rise 9.4% to A$2.275, set for their best day since May 13, if gains hold

** Earlier in the day, the radiopharmaceutical co hit its highest level since May 29

** Co says results from diagnostic Phase II trial for Cu-SARTATE shows its safe and highly effective for detecting lesions in patients with neuroendocrine tumours

** Cu-SARTATE is a product being developed by co for diagnosing, staging, and treating cancers including neuroblastoma and neuroendocrine tumors

** Co plans to rapidly hold discussions with the FDA to initiate a diagnostic registrational Phase III study of the product

** About 3.3 mln shares change hands vs 30-day average trading volume of 3.1 mln shares

** Stock down ~45% this year, including the day's move

 (Reporting by John Biju in Bengaluru)

 ((John.Biju@thomsonreuters.com;))